The Modern Financial Terminal

Subscribe for $2

Trusted by leading companies and financial institutions

Daiichi Sankyo Co Stock 4568.T

Currency:

Price

2,939.00 JPY

Today +/-

-11.50 JPY

Today %

-0.39 %

Ticker
4568.T

ISIN
JP3475350009

Daiichi Sankyo Co stock price

Weekly

Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Daiichi Sankyo Co stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Daiichi Sankyo Co stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Daiichi Sankyo Co stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Daiichi Sankyo Co's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Daiichi Sankyo Co Stock Price History

Date	Daiichi Sankyo Co Price
2/18/2026	2,939.00 JPY
2/17/2026	2,950.50 JPY
2/16/2026	2,955.00 JPY
2/13/2026	2,937.50 JPY
2/12/2026	2,906.00 JPY
2/10/2026	2,983.50 JPY
2/9/2026	2,952.00 JPY
2/6/2026	2,869.00 JPY
2/5/2026	2,934.00 JPY
2/4/2026	2,907.00 JPY
2/3/2026	2,935.00 JPY
2/2/2026	2,916.50 JPY
1/30/2026	2,836.00 JPY
1/29/2026	2,931.00 JPY
1/28/2026	2,928.00 JPY
1/27/2026	3,044.00 JPY
1/26/2026	3,120.00 JPY
1/23/2026	3,133.00 JPY
1/22/2026	3,139.00 JPY
1/21/2026	3,181.00 JPY
1/20/2026	3,220.00 JPY

Daiichi Sankyo Co Revenue, EBIT, Net Income

3 Years
5 Years
10 Years
25 Years
Max

Loading chart...

Revenue

EBIT

Net Income

Details

Daiichi Sankyo Co Income Statement, Balance Sheet, Cash Flow Statement

REVENUE (T JPY)

REVENUE GROWTH (%)

GROSS MARGIN (%)

GROSS INCOME (T JPY)

NET INCOME (B JPY)

NET INCOME GROWTH (%)

DIVIDEND (JPY)DIV. (JPY)

DIVIDEND GROWTH (%)DIV. GROWTH (%)

SHARES (B)

DOCUMENTS

2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e	2027e	2028e
0.93	0.93	0.88	0.84	0.95	0.97	0.94	1	1.12	0.92	0.99	0.96	0.96	0.93	0.98	0.96	1.04	1.28	1.6	1.89	2.17	2.38	2.63
–	0.39	-5.31	-4.31	13.06	1.60	-2.97	6.30	12.06	-17.78	7.30	-3.18	0.53	-3.17	5.60	-1.96	8.56	22.36	25.28	17.77	15.25	9.69	10.31
68.60	71.47	73.35	74.54	70.80	70.88	71.38	68.57	64.02	64.86	67.70	63.42	63.96	60.78	65.04	64.85	66.19	71.57	74.07	77.96	67.64	61.67	55.90
0.64	0.66	0.65	0.63	0.67	0.69	0.67	0.68	0.72	0.6	0.67	0.61	0.61	0.57	0.64	0.62	0.69	0.91	1.19	1.47	0	0	0
87.34	78.55	97.66	-215.5	41.85	70.12	10.38	66.62	60.94	322.12	82.28	53.47	60.28	93.41	129.07	75.96	66.97	109.19	200.73	295.76	323.03	386.37	467.8
–	-10.07	24.33	-320.66	-119.42	67.55	-85.19	541.64	-8.52	428.56	-74.46	-35.02	12.75	54.95	38.18	-41.15	-11.83	63.04	83.84	47.34	9.22	19.61	21.07
16.67	20.00	21.67	25.00	23.33	20.00	20.00	20.00	20.00	20.00	20.00	21.67	23.33	23.33	23.33	25.17	27.00	28.50	35.00	60.00	108.00	143.70	173.49
–	19.98	8.35	15.37	-6.68	-14.27	–	–	–	–	–	8.35	7.66	–	–	7.89	7.27	5.56	22.81	71.43	80.00	33.06	20.73
0.73	0.73	0.72	0.71	0.7	0.71	0.71	0.71	0.71	0.71	2.07	2.02	1.99	1.95	1.95	1.94	1.92	1.92	1.92	1.9	0	0	0
–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Details

Keystats

ⓘ

Revenue and Growth

The Daiichi Sankyo Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Daiichi Sankyo Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

ASSETS

CASH BALANCE (B JPY)

RECEIVABLES (B JPY)

OTHER RECEIVABLES (B JPY)OTHER REC. (B JPY)

INVENTORIES (B JPY)

OTHER CURRENT ASSETS (B JPY)OTHER CURRENT LIAB. (B JPY)

CURRENT ASSETS (T JPY)

TANGIBLE ASSETS (B JPY)

LONG-TERM INVESTMENTS (B JPY)LONG-T. INVEST. (B JPY)

LONG-TERM RECEIVABLES (B JPY)LONG-T. REC. (B JPY)

INTANGIBLE ASSETS (B JPY)INTANGIBLE ASSETS (B JPY)

GOODWILL (B JPY)

OTHER NON-CURRENT ASSETS (B JPY)OTHER NON-CURRENT ASSETS (B JPY)

NON-CURRENT ASSETS (T JPY)

TOTAL ASSETS (T JPY)

LIABILITIES

COMMON STOCK (B JPY)

ADDITIONAL PAID-IN CAPITAL (B JPY)

RETAINED EARNINGS (T JPY)

OTHER EQUITY (B JPY)OTHER EQUITY (B JPY)

UNREALIZED GAINS/LOSSES (B JPY)UNREAL. GAINS/LOSSES (B JPY)

EQUITY (T JPY)

LIABILITIES (B JPY)

PROVISIONS (B JPY)

OTHER SHORT-TERM LIABILITIES (B JPY)OTHER SHORT-TERM LIAB. (B JPY)

SHORT-TERM DEBTS (B JPY)SHORT-TERM DEBTS (B JPY)

SHORT-TERM PORTION OF LONG-TERM DEBTS (B JPY)LONG-TERM DEBT PORTION (B JPY)

SHORT-TERM RECEIVABLES (T JPY)SHORT-TERM REC. (T JPY)

LONG-TERM LIABILITIES (B JPY)LONG-T. LIAB. (B JPY)

DEFERRED TAXES (B JPY)

OTHER LIABILITIES (B JPY)OTHER LIAB. (B JPY)

LONG-TERM LIABILITIES (T JPY)LONG-T. LIABILITIES (T JPY)

DEBT (T JPY)

TOTAL CAPITAL (T JPY)

2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025

514.99	621.51	574.14	312.03	337.54	419.69	320.26	372.3	505.33	374.71	514.34	514.39	594.5	560.52	673.23	671.7	778.75	607.61	876.87	714.26
239.57	196.43	166.69	194.49	210.22	203.27	226.35	235.81	243	218.18	228.62	208.67	210.77	360.38	282.54	201.03	214.58	280.68	344.8	435.51
0	0	0	0	0	0	0	0	27.19	24.49	21.06	23.69	21.26	59.64	27.24	31.36	52.36	68.56	109.41	183.59
121.69	107.76	98.16	139.48	143.22	142.79	169.66	174.43	189.41	150.09	144.27	153.14	172.59	176.07	173.36	200.86	217.91	301.61	438.11	514.91
82.22	90.14	87.54	137.51	128.77	128.32	145.26	161.1	25.67	17.87	216.98	297.9	202.43	236.58	227.75	163.47	81.68	236.59	404.84	61.17
0.96	1.02	0.93	0.78	0.82	0.89	0.86	0.94	0.99	0.79	1.13	1.2	1.2	1.39	1.38	1.27	1.35	1.5	2.17	1.91
289.71	248.86	221.26	250.11	249.54	237.71	261.24	303.43	316.3	266.49	250.17	217.77	217.95	229.09	247.05	265.28	304.07	348.91	421.69	498.52
256.34	262.24	216.04	153.73	137.04	102.42	104.56	129.19	138.48	593.23	167.62	141.54	179.98	116.3	97.62	141.01	132.72	131.15	147.97	144.77
6.15	1.62	1.3	0.61	0	0	0	0	2.6	2.06	1.78	0.74	0.89	0.8	0.74	0.42	0.18	0.04	0	0
26.38	41.58	75.67	115.18	107.12	89.61	150.55	149.91	171.42	199.41	210.4	217.04	173.54	169.47	172.5	172.82	163.88	159.61	168.3	235.84
9.79	18.57	15.4	77.38	73.77	67.32	82.74	73.54	85.52	71.37	78.69	78.45	75.48	77.85	76.76	77.71	83.56	98.33	108.5	108.43
49.27	48.13	31.68	114.08	102.27	89.11	57.86	44.35	149.11	64.39	66.6	61.65	48.38	101.36	126.83	159.52	191.72	275.8	440.66	559.13
0.64	0.62	0.56	0.71	0.67	0.59	0.66	0.7	0.86	1.2	0.78	0.72	0.7	0.69	0.72	0.82	0.88	1.01	1.29	1.55
1.6	1.64	1.49	1.49	1.49	1.48	1.52	1.64	1.85	1.98	1.9	1.91	1.9	2.09	2.11	2.09	2.22	2.51	3.46	3.46

50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50	50
179.86	179.86	179.86	105.19	105.19	105.19	105.19	105.19	105.27	105.27	103.93	103.75	94.63	94.63	94.63	94.49	0	0	1.96	0
0.94	0.97	1.03	0.76	0.75	0.78	0.75	0.77	0.72	0.99	0.99	1.01	1.03	1.15	1.24	1.28	1.17	1.23	1.39	1.46
0.74	4.96	-16.26	-51.29	-58.78	-82.44	-100.41	-59.04	121.75	169.04	146.72	124.49	120.51	115.17	82.1	111.48	168.15	200.87	284	263.69
80.25	72.36	48.54	19.88	27.46	16.56	22.31	34.21	0	0	0	0	0	0	0	0	0	0	0	0
1.25	1.28	1.29	0.88	0.87	0.87	0.82	0.9	0.99	1.32	1.3	1.29	1.3	1.41	1.47	1.53	1.39	1.48	1.72	1.77
65.6	56.44	46.41	59.42	66.54	58.41	61.82	59.8	66.54	50.05	50.97	54.76	68.81	73.47	70.15	68.69	68.54	80.39	88.74	672.72
0	0	0	0	0	0	0	88.99	0	0	0	0	0	0	0	0	0	0	0	0
157.69	216.51	148.04	184.58	182.05	172.93	262.06	221.25	233.24	226.37	307.94	271.52	263.78	270.66	231.04	255.2	295.64	397.55	621.82	646.16
13.55	8.56	0.07	261.11	15.02	25.83	71.08	45.34	67.03	0	0	0	0	0	0	0	0	0	0	0
0	0	0	3.42	5.2	49.78	0	20.73	94.38	21.08	20.79	0.54	20.52	40.42	49.88	29.68	31.09	52.33	12.84	15.11
0.24	0.28	0.19	0.51	0.27	0.31	0.39	0.44	0.46	0.3	0.38	0.33	0.35	0.38	0.35	0.35	0.4	0.53	0.72	1.33
3.37	1.53	0.02	63.82	270.92	224.04	204	200.92	265.43	203.56	182.83	281.61	261.59	221.5	216.45	196.5	182.53	140.53	143.16	140.78
23.93	36.15	26.72	5.43	29.24	28.46	52.08	45.11	39.84	88.36	33.68	32.29	18.68	17.17	15.64	17.52	12.44	12.65	12.86	11.07
82.85	45.5	22.12	28.2	31.03	33.08	34.68	46.19	80.06	85.84	70.8	102.83	131.35	215.14	216.18	245.54	280.29	379.59	893.11	926.83
0.11	0.08	0.05	0.1	0.33	0.29	0.29	0.29	0.39	0.38	0.29	0.42	0.41	0.45	0.45	0.46	0.48	0.53	1.05	1.08
0.35	0.36	0.24	0.61	0.6	0.59	0.69	0.73	0.85	0.68	0.67	0.74	0.76	0.84	0.8	0.81	0.87	1.06	1.77	2.41
1.59	1.64	1.53	1.49	1.47	1.46	1.51	1.63	1.84	1.99	1.96	2.03	2.06	2.25	2.27	2.35	2.26	2.55	3.5	4.18

Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Daiichi Sankyo Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Daiichi Sankyo Co's financial health and stability.

Assets

Daiichi Sankyo Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Daiichi Sankyo Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Daiichi Sankyo Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Daiichi Sankyo Co's financial standing, aiding in investment evaluations and risk assessments.

NET INCOME (B JPY)

DEPRECIATION AND AMORTIZATION B JPYDEPRECIATION (B JPY)

DEFERRED TAXES (M JPY)

CHANGES IN WORKING CAPITAL (B JPY)CHANGES IN WORKING CAPITAL (B JPY)

NON-CASH ITEM (B JPY)

PAID INTEREST (B JPY)

PAID TAXES (B JPY)

Net Cash Flow from Operating Activities (B JPY)NET CASH FLOW FROM OPERATING ACTIVITIES (B JPY)

CAPITAL EXPENDITURES (M JPY)

CASH FLOW FROM INVESTING ACTIVITIES (B JPY)CASH FLOW FROM INVESTING ACTIVITIES (B JPY)

CASH FLOW FROM OTHER INVESTING ACTIVITIES (B JPY)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B JPY)

INTEREST INCOME AND EXPENSES (M JPY)

NET DEBT CHANGE (B JPY)NET DEBT CHANGE (B JPY)

Net change in equity (M JPY)NET CHANGE IN EQUITY (M JPY)

CASH FLOW FROM FINANCING ACTIVITIES (B JPY)CASH FLOW FROM FINANCING ACTIVITIES (B JPY)

OTHER ITEMS OF FINANCING CASH FLOWS (B JPY)CASH FLOW FROM OTHER FINANCING ACTIVITIES (B JPY)

TOTAL DIVIDENDS PAID (M JPY)

NET CHANGE IN CASH FLOW (B JPY)

FREE CASH FLOW (M JPY)

SHARE-BASED COMPENSATION (M JPY)

2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
136.89	126.91	166.86	-308.26	97.37	120.42	33.92	92.1	99.78	79.94	122.39	87.79	81.02	85.83	141.16	74.12	73.52	126.85
42.55	43.58	42.33	415.57	55.09	55.21	57.38	52.54	51.49	42.02	44.31	47.37	46.68	46.17	52.61	57.38	58.25	67.79
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-45.72	38.8	-90.23	-57.21	-2.05	-26.27	-57.98	-13.24	-118.25	-19.45	2.57	-26.98	-46.07	-45.47	6.95	69.59	0.21	-81.71
-1.29	-101.99	-50.77	28.26	-20.17	-8.22	59.25	-2.15	4.3	40.27	5.01	28.05	26.81	5.51	-4.12	-8.89	7.26	1.58
0.31	0.25	0.13	0.65	3.64	2.89	3.27	4.12	11.18	1.73	1.4	1.51	2.04	1.77	2.53	1.84	1.78	2.08
53	61.95	60.52	58.61	30.41	34.74	31.9	23.56	54.81	21.87	37.44	30.37	22.17	36.15	26.18	24.53	22.58	46.25
132.44	107.3	68.19	78.36	130.23	141.14	92.57	129.25	37.3	142.78	174.28	136.23	108.44	92.03	196.6	192.21	139.23	114.51
-48,586	-42,952	-51,586	-44,602	-31,157	-36,132	-63,700	-78,862	-54,514	-94,630	-69,397	-52,962	-38,008	-66,613	-52,565	-64,093	-76,682	-67,366
-39.26	45.31	-49.44	-413.85	42.63	-62.97	-125.1	-109.28	-161.37	-21.28	-5.97	-96.79	108.57	-142.52	81.67	-39.25	212.34	-257.78
9.33	88.26	2.15	-369.25	73.78	-26.83	-61.4	-30.42	-106.85	73.35	63.43	-43.83	146.58	-75.91	134.24	24.85	289.02	-190.42
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-2.38	1.02	-2.38	197.32	-39.66	16.15	-18.75	-15.09	143.62	120.6	-22.98	80	0	-20	-36.41	-40.39	-34.49	-34.95
-13,691	-162	-33,407	-45,817	-23	-32	-11	-12	-31	-25	-50,239	-50,094	-50,084	-45	-85	-100,190	-15	-24
-50.1	-40.77	-82.9	98.06	-89.12	-25.98	-50.2	-57.33	100.32	-132.2	-122.93	-15.02	-101.77	-66.2	-91.64	-202.43	-86.23	-89.59
-16.71	-1.57	-0.1	-0.15	-0.18	0.15	10.81	0.01	-1.03	0.08	-1.25	-1.04	-5.26	-0.82	-9.79	-12.91	0	0
-17,326	-40,049	-47,016	-53,292	-49,256	-42,246	-42,240	-42,240	-42,238	-42,254	-48,468	-43,889	-46,420	-45,339	-45,356	-48,946	-51,730	-54,616
46.87	112.24	-68.88	-266.56	81.44	43.19	-89.73	-21.75	-8.08	6.3	32.79	23.89	111.65	-114.55	181.03	-43.64	281.93	-220.56
83,850	64,350	16,608	33,759	99,075	105,007	28,869	50,385	-17,210	48,146	104,884	83,272	70,431	25,420	144,036	128,114	62,544	47,148
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Daiichi Sankyo Co stock margins

The Daiichi Sankyo Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Daiichi Sankyo Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Daiichi Sankyo Co.

3 Years
5 Years
10 Years
25 Years
Max

Loading chart...

Gross margin

EBIT margin

Profit margin

Details

Daiichi Sankyo Co Stock Sales Revenue, EBIT, Earnings per Share

The Daiichi Sankyo Co earnings per share therefore indicates how much revenue Daiichi Sankyo Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

3 Years
5 Years
10 Years
25 Years
Max

Loading chart...

Sales per Share

EBIT per share

Earnings per Share

Details

Daiichi Sankyo Co business model

Daiichi Sankyo Co Ltd is a company specialized in the production of medicines. The company was founded in 2005 and was formed from the merger of two Japanese pharmaceutical companies. However, the history of Daiichi Sankyo dates back to 1899 when the Daiichi Group and Sankyo Renkyu merged to form a cooperative. Both companies had been active in the pharmaceutical business since the 1960s and were specialized in the development and production of drugs. Daiichi Sankyo's business model is focused on developing and globally marketing innovative drugs. The company focuses on researching and marketing drugs for the treatment of cancer, cardiovascular diseases, and infectious diseases. Daiichi Sankyo is divided into different divisions. The pharmaceutical division is the company's most important business segment. Here, drugs for various applications are developed and produced, including medications for the therapy of cancer, cardiovascular diseases, and infections. Another division is the medical devices division. Here, medical devices such as catheters and stents for the treatment of cardiovascular diseases, as well as endoscopic devices for the diagnosis and therapy of gastrointestinal diseases, are manufactured. Another important area is the diagnostics division. Here, diagnostic test systems for various applications are developed and manufactured. Some of Daiichi Sankyo's best-known products include the cancer drug Trastuzumab Emtansin and the anticoagulant drug Prasugrel. Daiichi Sankyo is a globally operating company headquartered in Tokyo, Japan. In addition, the company has branches in North, Central, and South America, Europe, Asia, and Oceania. The company places great importance on research and development and participates in numerous collaborations and partnerships with universities and other companies. The goal is to constantly develop new groundbreaking drugs and contribute to the improvement of disease treatment. Overall, Daiichi Sankyo employs approximately 15,000 people worldwide and generates an annual revenue of around 8 billion euros. The company is thus one of the leading companies in the pharmaceutical and medical technology industry and will remain an important player in the global healthcare market in the future. Daiichi Sankyo Co is one of the most popular companies on Eulerpool.com.

Daiichi Sankyo Co SWOT Analysis

Helpful

Harmful

Internal

Strengths

Daiichi Sankyo Co Ltd possesses several strengths that contribute to its success in the pharmaceutical industry:

Strong brand reputation and recognition globally
Diversified portfolio of products across therapeutic areas
Robust research and development capabilities
Global presence with a strong foothold in key markets
Strong financial position and healthy revenue growth

Weaknesses

Despite its strengths, Daiichi Sankyo Co Ltd also faces certain weaknesses that pose challenges to its growth:

Overreliance on a few key products for a significant portion of revenue
Limited market share in certain regions
High competition within the pharmaceutical industry
Dependency on external suppliers for raw materials
Regulatory hurdles in entering new markets

External

Opportunities

There are several opportunities that Daiichi Sankyo Co Ltd can capitalize on to further expand its business:

Increasing demand for innovative pharmaceutical solutions
Growing aging population in many countries
Expansion into emerging markets with high growth potential
Strategic collaborations and partnerships
Advancements in technology for drug discovery and development

Threats

Daiichi Sankyo Co Ltd faces certain threats that need to be carefully addressed to mitigate potential risks:

Intense competition from generic drug manufacturers
Stringent regulations and increasing pricing pressures
Economic downturns impacting consumer spending on healthcare
Rapidly evolving healthcare landscape and changing patient preferences
Intellectual property infringements and counterfeit drugs

Daiichi Sankyo Co Eulerpool Fair Value

Loading chart...

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Daiichi Sankyo Co historical P/E ratio, EBIT multiple, and P/S ratio

Daiichi Sankyo Co shares outstanding

The number of shares was Daiichi Sankyo Co in 2025 — This indicates how many shares 1.897 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

3 Years
5 Years
10 Years
25 Years
Max

Loading chart...

Number of stocks

Details

Daiichi Sankyo Co stock splits

In Daiichi Sankyo Co's history, there have been no stock splits.

Daiichi Sankyo Co dividend history and estimates

In 2025, Daiichi Sankyo Co paid a dividend amounting to 60 JPY. Dividend means that Daiichi Sankyo Co distributes a portion of its profits to its owners.

3 Years
5 Years
10 Years
25 Years
Max

Loading chart...

Dividend

Dividend (Estimate)

Details

Daiichi Sankyo Co dividend payout ratio

In 2025, Daiichi Sankyo Co had a payout ratio of 71.89%. The payout ratio indicates the percentage of the company's profits that Daiichi Sankyo Co distributes as dividends.

3 Years
5 Years
10 Years
25 Years
Max

Loading chart...

Payout ratio

Details

Unfortunately, there are currently no price targets and forecasts available for Daiichi Sankyo Co.

Daiichi Sankyo Co Earnings Calls

Daiichi Sankyo Co Earnings Estimates

Date	EPS estimate	Revenue Estimate	Quarterly report
4/25/2024	4.43 JPY	399.94 B JPY	2024 Q4
1/29/2024	16.62 JPY	408.88 B JPY	2024 Q3
7/27/2023	27.98 JPY	345.1 B JPY	2024 Q1
4/25/2023	-4.85 JPY	305.74 B JPY	2023 Q4
1/30/2023	19.35 JPY	331.42 B JPY	2023 Q3
10/31/2022	14.11 JPY	289.98 B JPY	2023 Q2
7/29/2022	12.79 JPY	266.4 B JPY	2023 Q1
4/27/2022	-7.97 JPY	241.73 B JPY	2022 Q4
1/31/2022	8.82 JPY	261.01 B JPY	2022 Q3
10/29/2021	10.86 JPY	257.54 B JPY	2022 Q2
7/30/2021	11.88 JPY	245.37 B JPY	2022 Q1
4/27/2021	-12.05 JPY	230.03 B JPY	2021 Q4
1/29/2021	11.36 JPY	261.69 B JPY	2021 Q3
10/30/2020	7.14 JPY	234.58 B JPY	2021 Q2
7/31/2020	13.84 JPY	241.11 B JPY	2021 Q1
4/27/2020	-11.97 JPY	223.97 B JPY	2020 Q4
1/31/2020	16.26 JPY	269.08 B JPY	2020 Q3
10/31/2019	12.54 JPY	236.35 B JPY	2020 Q2
7/31/2019	10.49 JPY	225.36 B JPY	2020 Q1
4/25/2019	-6.17 JPY	217.68 B JPY	2019 Q4
1/31/2019	12.66 JPY	261.47 B JPY	2019 Q3
10/31/2018	8.61 JPY	222.32 B JPY	2019 Q2
7/31/2018	9.39 JPY	229.95 B JPY	2019 Q1
4/27/2018	-3.42 JPY	227.04 B JPY	2018 Q4
1/31/2018	11.35 JPY	261.12 B JPY	2018 Q3
10/31/2017	3.88 JPY	232.11 B JPY	2018 Q2
7/31/2017	13.74 JPY	235.28 B JPY	2018 Q1
5/11/2017	-5.89 JPY	216.58 B JPY	2017 Q4
1/31/2017	10.71 JPY	252 B JPY	2017 Q3
10/31/2016	10.58 JPY	229.7 B JPY	2017 Q2
7/29/2016	10.66 JPY	225.5 B JPY	2017 Q1
5/12/2016	-13.22 JPY	226.57 B JPY	2016 Q4
1/29/2016	9.28 JPY	263.24 B JPY	2016 Q3
10/30/2015	10.12 JPY	240.84 B JPY	2016 Q2
7/31/2015	10.47 JPY	234.16 B JPY	2016 Q1
1/30/2015	3.5 JPY	263.6 B JPY	2015 Q3
10/31/2014	3.97 JPY	273.59 B JPY	2015 Q2
7/31/2014	9.43 JPY	216.56 B JPY	2015 Q1
1/31/2014	9.9 JPY	272.32 B JPY	2014 Q3
10/31/2013	7.91 JPY	268.87 B JPY	2014 Q2
7/31/2013	7.81 JPY	252.73 B JPY	2014 Q1
1/31/2013	3.27 JPY	247.86 B JPY	2013 Q3
10/31/2012	0.21 JPY	230.58 B JPY	2013 Q2
7/31/2012	11.36 JPY	246.57 B JPY	2013 Q1
5/11/2012	-0.47 JPY	240.8 B JPY	2012 Q4
1/31/2012	12.12 JPY	251.27 B JPY	2012 Q3
10/31/2011	4.63 JPY	241.87 B JPY	2012 Q2
7/29/2011	8.2 JPY	232.46 B JPY	2012 Q1
5/12/2011	-0.18 JPY	224.93 B JPY	2011 Q4
1/31/2011	7.84 JPY	251.6 B JPY	2011 Q3
10/29/2010	3.27 JPY	252.73 B JPY	2011 Q2
7/30/2010	7.14 JPY	254.26 B JPY	2011 Q1

...

Eulerpool ESG Scorecard© for the Daiichi Sankyo Co stock

Eulerpool World ESG Rating (EESG©)

92/ 100

🌱 Environment

👫 Social

🏛️ Governance

Environment

Scope 1 - Direct Emissions	85,245
Scope 2 - Indirect emissions from purchased energy	23,994
Scope 3 - Indirect emissions within the value chain	4,408,736
Total CO₂ emissions	109,239
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees	41
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Daiichi Sankyo Co shareholders

%	Name	Stocks	Change	Date
4.73870 %	Capital Research Global Investors	89,914,541	-25,947,994	4/30/2025
4.65372 %	Nomura Asset Management Co., Ltd.	88,302,079	-914,200	7/31/2025
4.52517 %	Nippon Life Insurance Company	85,863,000	0	3/31/2025
2.98306 %	The Vanguard Group, Inc.	56,602,241	-55,700	7/31/2025
2.96700 %	Asset Management One Co., Ltd.	56,297,400	-1,336,200	7/31/2025
2.17804 %	Nikko Asset Management Co., Ltd.	41,327,193	-727,200	7/31/2025
2.10122 %	Daiwa Asset Management Co., Ltd.	39,869,748	-16,904	7/31/2025
2.04998 %	BlackRock Japan Co., Ltd.	38,897,400	38,234,800	10/15/2024
1.92993 %	BlackRock Fund Advisors	36,619,601	36,578,301	10/15/2024
1.47682 %	Norges Bank Investment Management (NBIM)	28,022,000	403,000	3/31/2025
1.46952 %	Wellington Management Company, LLP	27,883,425	-8,283,958	6/30/2025
1.31830 %	Mizuho Bank, Ltd.	25,014,130	0	7/31/2025
1.23210 %	BlackRock Institutional Trust Company, N.A.	23,378,534	-23,689,109	10/15/2024
1.02274 %	Nuveen LLC	19,406,040	67,200	7/31/2025
0.92267 %	Mitsubishi UFJ Asset Management Co., Ltd.	17,507,270	-33,982	7/31/2025
0.82135 %	MFS Investment Management	15,584,800	1,831,900	6/30/2025
0.80591 %	BlackRock Asset Management Ireland Limited	15,291,746	15,291,746	10/15/2024
0.75465 %	Geode Capital Management, L.L.C.	14,319,072	-21,769	6/30/2025
0.68008 %	BlackRock Advisors (UK) Limited	12,904,146	-71,200	7/31/2025
0.49784 %	BlackRock Investment Management (UK) Ltd.	9,446,252	-368,485	10/15/2024
0.45185 %	JP Morgan Asset Management	8,573,583	360,700	7/31/2025
0.44722 %	Mizuho Trust & Banking Co., Ltd.	8,485,870	0	7/31/2025
0.40328 %	Goldman Sachs Asset Management, L.P.	7,651,964	0	7/31/2025
0.36159 %	BlackRock (Netherlands) B.V.	6,861,045	6,861,045	10/15/2024
0.34459 %	Fidelity Management & Research Company LLC	6,538,376	186,700	7/31/2025
0.31400 %	BlackRock Financial Management, Inc.	5,958,000	0	7/31/2025
0.29022 %	Mizuho Securities Co., Ltd.	5,506,777	1,898,792	7/31/2025
0.29013 %	DWS Investments UK Limited	5,505,098	22,609	7/31/2025
0.28990 %	Charles Schwab Investment Management, Inc.	5,500,732	12,285	7/31/2025
0.23986 %	Amundi Asset Management, SAS	4,551,323	-83,000	7/31/2025
0.23595 %	APG Asset Management N.V.	4,477,022	130,444	12/31/2024
0.22854 %	Carmignac Gestion	4,336,468	16,510	5/31/2025
0.22435 %	BlackRock (Luxembourg) S.A.	4,257,006	3,451,606	10/15/2024
0.21945 %	M&G Investment Management Ltd.	4,164,000	30,500	6/30/2025
0.21314 %	Capital International, Inc.	4,044,200	-232,586	4/30/2025
0.20738 %	Invesco Advisers, Inc.	3,934,911	728	7/31/2025
0.20014 %	DWS Investment GmbH	3,797,562	2,057	7/31/2025
0.19877 %	UBS Asset Management (UK) Ltd.	3,771,533	148,015	7/31/2025
0.19820 %	California State Teachers Retirement System	3,760,738	1,218,329	6/30/2024
0.19795 %	State Street Global Advisors (US)	3,756,047	9,733	7/31/2025
0.19775 %	RBC Global Asset Management (Asia) Limited	3,752,298	431,400	6/30/2025
0.18720 %	BlackRock Investment Management, LLC	3,551,957	1,791,271	10/15/2024
0.17759 %	California Public Employees' Retirement System	3,369,698	-281,340	6/30/2024
0.17159 %	HSBC Global Asset Management (UK) Limited	3,255,753	55,737	6/30/2025
0.17023 %	Medipal Holdings Corp	3,230,089	-1,850,000	3/31/2024
0.16663 %	Aviva Investors Global Services Limited	3,161,728	8,968	6/30/2025
0.16032 %	CPP Investment Board	3,042,000	-885,000	3/31/2024
0.15808 %	Toray Industries Inc	2,999,583	0	3/31/2024
0.14650 %	BlackRock Advisors, LLC	2,779,723	2,730,123	10/15/2024
0.14561 %	OrbiMed Advisors, LLC	2,762,850	0	4/30/2025
0.14327 %	Royal London Asset Management Ltd.	2,718,500	36,100	6/30/2025
0.14200 %	TD Asset Management Inc.	2,694,407	5,100	6/30/2025
0.14179 %	AQR Capital Management, LLC	2,690,406	1,622,400	6/30/2025
0.13823 %	Janus Henderson Investors	2,622,800	1,797,800	6/30/2025
0.12629 %	Handelsbanken Kapitalförvaltning AB	2,396,222	-28,800	6/30/2025
0.12368 %	Legal & General Investment Management Ltd.	2,346,793	-28,100	7/31/2025
0.11931 %	BlackRock Investment Management (Australia) Ltd.	2,263,767	2,147,167	10/15/2024
0.11883 %	UBS Fund Management (Switzerland) AG	2,254,728	-1,600	7/31/2025
0.11704 %	Mellon Investments Corporation	2,220,711	-43,500	7/31/2025
0.11645 %	BNP Paribas Asset Management USA, Inc.	2,209,500	0	6/30/2025
0.11348 %	Nordea Funds Oy	2,153,300	28,200	6/30/2025
0.11018 %	State Street Global Advisors (UK) Ltd.	2,090,704	41,000	7/31/2025
0.10923 %	BlackRock Asset Management Canada Limited	2,072,543	794,643	10/15/2024
0.10042 %	MFS Institutional Advisors, Inc	1,905,440	-135,400	6/30/2025
0.09139 %	Kissei Pharmaceutical Co Ltd	1,734,000	0	3/31/2024
0.09027 %	Northern Trust Investments, Inc.	1,712,867	6,800	7/31/2025
0.08630 %	Rheos Capital Works Inc.	1,637,547	482,446	9/30/2024
0.07920 %	Nissay Asset Management Corp.	1,502,819	97,059	2/28/2025
0.07728 %	Capital World Investors	1,466,300	1,420,300	6/30/2025
0.07581 %	Schroder Investment Management Ltd. (SIM)	1,438,400	-26,400	6/30/2025
0.07152 %	JPMorgan Asset Management (Asia Pacific) Limited	1,357,000	0	6/30/2025
0.07115 %	Caixabank Asset Management SGIIC, S.A.U.	1,350,084	0	5/31/2025
0.07041 %	Northern Trust Global Investments Limited	1,336,037	83,937	6/30/2025
0.06909 %	Capfi Delen Asset Management	1,311,000	-5,000	3/31/2025
0.06732 %	Cardano Asset Management NV	1,277,451	-40,036	6/30/2025
0.06730 %	BNP Paribas Asset Management UK Limited	1,277,000	258,700	6/30/2025
0.06595 %	Nomura Asset Management (UK) Ltd.	1,251,300	4	1/31/2025
0.06462 %	Dimensional Fund Advisors, L.P.	1,226,138	-9,000	7/31/2025
0.06436 %	Sumitomo Mitsui DS Asset Management Company, Limited	1,221,204	92,500	7/31/2025
0.06311 %	UBS Asset Management (Switzerland)	1,197,515	-6,800	7/31/2025
0.06241 %	Norinchukin Zenkyoren Asset Management Co., Ltd.	1,184,235	-12,000	7/31/2025
0.05908 %	Zürcher Kantonalbank (Asset Management)	1,121,077	4,000	6/30/2025
0.05765 %	Candriam Luxembourg S.A.	1,093,898	-12,600	6/30/2025
0.05691 %	Deka Investment GmbH	1,079,883	0	7/31/2025
0.05466 %	SEB Investment Management AB	1,037,123	-808	6/30/2025
0.05465 %	Vanguard Investments Australia Ltd.	1,036,921	-5,470	6/30/2025
0.05347 %	Franklin Templeton Portfolio Advisors, Inc	1,014,600	4,900	7/31/2025
0.05184 %	JPMorgan Asset Management U.K. Limited	983,600	-34,600	6/30/2025
0.04839 %	Storebrand Kapitalforvaltning AS	918,102	5,000	6/30/2025
0.04806 %	Vanguard Global Advisers LLC	911,850	-19,500	6/30/2025
0.04785 %	DBX Advisors LLC.	907,938	-5,800	7/31/2025
0.04743 %	Hitachi Ltd	900,000	0	3/31/2024
0.04656 %	PGGM Vermogensbeheer B.V.	883,425	-148,219	3/31/2025
0.04243 %	Danske Bank Asset Management	805,118	-1	6/30/2025
0.04243 %	Matthews International Capital Management, L.L.C.	805,000	-300	7/31/2025
0.04224 %	BMO Asset Management Inc.	801,447	0	7/31/2025
0.04215 %	Medical Strategy GmbH	799,800	-209,200	11/30/2024
0.04158 %	Första AP-Fonden	789,000	340,300	12/31/2024
0.04024 %	Jyske Invest Fund Management A/S	763,511	113,700	6/30/2025
0.03891 %	Florida State Board of Administration	738,310	177,495	3/31/2025

...

Daiichi Sankyo Co Executives and Management Board

Mr. Sunao Manabe

(69)

Daiichi Sankyo Co Chairman of the Board, Chairman of the Executive Board, Chief Executive Officer, Representative Director (since 2012)

Compensation 385 M JPY

Mr. Hiroyuki Okuzawa

(61)

Daiichi Sankyo Co President, Executive President, Chief Operating Officer, Representative Director (since 2018)

Compensation 252 M JPY

Mr. Shoji Hirashima

(63)

Daiichi Sankyo Co Senior Managing Executive Officer, Manager of Japan Business Unit, Representative Director

Compensation 166 M JPY

Mr. Takashi Fukuoka

(63)

Daiichi Sankyo Co Senior Managing Executive Officer, Head of Global Corporate Strategy, CStO, Director

Compensation 147 M JPY

Mr. Takashi Matsumoto

(60)

Daiichi Sankyo Co Chief Human Resource Officer, Managing Executive Officer, Head of Global HR, Director

...

Most common questions regarding Daiichi Sankyo Co

The business model of Daiichi Sankyo Co Ltd revolves around the research, development, manufacturing, and marketing of pharmaceutical products. As a global pharmaceutical company, Daiichi Sankyo focuses on innovative solutions in the areas of cardiovascular, oncology, and immunology. With a commitment to improving human health and well-being, Daiichi Sankyo strives to deliver high-quality medications that address unmet medical needs. Through strategic collaborations and acquisitions, the company aims to expand its product portfolio and reach a wider patient population. Daiichi Sankyo's business model centers on providing effective and safe healthcare solutions while contributing to scientific advancements in the field of pharmaceuticals.

Daiichi Sankyo Co Ltd is a globally leading company in the pharmaceutical industry, focusing on the research and development of new innovative drugs. The company was formed in 2005 through the merger of two Japanese companies, Daiichi Pharmaceutical Co Ltd and Sankyo Co Ltd, and is headquartered in Tokyo, Japan. Daiichi Sankyo's business model consists of three main divisions: Pharma, Generics, and Consumer Healthcare. In the Pharma division, the company develops and distributes innovative drugs in the areas of oncology, cardiovascular diseases, pain management, and infectious diseases. Daiichi Sankyo utilizes a combination of preclinical research, clinical trials, and partnerships with other companies in the industry. An important component of Daiichi Sankyo's business model is the Generics division, where the company develops and distributes lower-cost versions of existing drugs. With this strategy, the company aims to expand its reach and generate higher revenue without bearing the high costs of researching and developing new medications. Daiichi Sankyo's Consumer Healthcare division includes products such as dietary supplements, vitamins, and medical foods. With this segment of the business, the company also aims to enter this market segment and expand its reach to a wider range of products. In the field of oncology, Daiichi Sankyo has developed and marketed some important drugs, including the cancer drugs Lonsurf and Enhertu. The company has also formed partnerships with other companies in the field of cancer research to create synergies and develop the best treatment options. In the cardiovascular diseases division, Daiichi Sankyo develops products such as the blood pressure medication Olmesartan and the antiplatelet drug Prasugrel. The company has also been involved in the development and marketing of the pain medication Celecoxib, used in the treatment of arthritis and other pain conditions. In pain management, Daiichi Sankyo develops the pain medication Tapentadol, used in the treatment of severe and chronic pain. The company has also formed partnerships with other companies in the field of pain management to expand its product range and provide better treatment options for patients. Overall, Daiichi Sankyo pursues a broad business model that includes the development of innovative products in various segments of the pharmaceutical industry, as well as the marketing of lower-cost versions of existing medications and the marketing of products in the Consumer Healthcare sector. With a strong focus on research and development, partnerships, and collaboration with other companies in the industry, the company is well positioned to continue expanding in the pharmaceutical industry and develop innovative solutions for patient healthcare.

Sector

Health

Industry

Pharmaceuticals

Number of shares

1,897,453,000

Employees

15,348

Revenue growth Ø5 years

14.4 %

EBIT growth Ø5 years

39.08 %

Net Income growth Ø5 years

31.24 %

Website daiichisankyo.co.jp

Country

🇯🇵

Currency

JPY

Initial public offering

Sep 28, 2005

ISIN

JP3475350009

Cusip

J11257102

Sedol

B0J7D91

Market capitalization

5.51 T JPY

Daiichi Sankyo Co Directors Dealings

Quality Investing

Details

8 / 10

PEG

1.44

P/E ratio

18.86

Forward P/E ratio 2026

17.26

Forward P/E ratio 2027

14.43

Forward P/E ratio 2028

11.92

P/S ratio

2.96

Forward P/S ratio

2.57

ROE (Return on Equity)

18.22 %

ROA (Return on Assets)

8.56 %

ROCE (Return on Capital Employed)

12.28 %

ROIC (Return on Invested Capital)

13.58 %

Dividend

108 JPY

Dividend yield

3.67 %

Dividend growth Ø5Y

31.95 %

Dividend payments per year

Dividend paid since

20 years

Dividend not reduced since

13 years

Dividend increased since

4 years

Dividend withholding tax

25.95 %

Daiichi Sankyo Co Peer Group

Astellas Pharma Inc

Chugai Pharmaceutical Co Ltd

Otsuka Holdings Co Ltd

Eisai Co Ltd

Shionogi & Co Ltd

Takeda Pharmaceutical Co Ltd

Daiichi Sankyo Co Eulerpool News

Daiichi Sankyo Co Earnings Calls

No Earnings Calls available for Daiichi Sankyo Co

Daiichi Sankyo Co News

All Daiichi Sankyo Co News

Daiichi Sankyo Co Ticker

Stock Exchange	Daiichi Sankyo Co Ticker
DÜSSELDORF	D4S.DU
FRANKFURT	D4S.F
JPX	4568.T
MUNICH	D4S.MU
PNK	DSKYF

Daiichi Sankyo Co FIGI

Daiichi Sankyo Co Ticker	Daiichi Sankyo Co FIGI
4568:JP	BBG000BWPLT1
4568:JT	BBG000BWPMB8
4568:JJ	BBG000BWPS89
4568:JE	BBG000BWPT41
4568:JI	BBG000BWPTF9
D4S:GR	BBG000DXRM40
D4S:GF	BBG000DXRMJ4
D4S:GD	BBG000DXRMZ6
D4S:GS	BBG000DXRNN7
D4S:GM	BBG000DXRNW7
D4S:GB	BBG000DXRP70
D4S:GI	BBG000DXRQL2
DSKYF:US	BBG000JG7CY2
DSKYF:PQ	BBG000JG7QS8
DSKYF:UV	BBG000JG7T11
4568:JU	BBG002QKCFJ5
4568JPY:EO	BBG005QKW358
4568JPY:XH	BBG005QKW385
4568JPY:XF	BBG005QKW3B1
4568JPY:XE	BBG005QKW3D9
4568JPY:XJ	BBG005QKW3F7
4568JPY:XL	BBG005QKW3H5
4568JPY:XG	BBG005QKW3J3
4568JPY:XO	BBG005QKW3K1
4568JPY:XS	BBG005QKW3Q5
4568JPY:XA	BBG005QKW3R4
4568JPY:E1	BBG005QKW3S3
4568JPY:XT	BBG005QKW3T2
4568JPY:XW	BBG005QKW3V9
4568JPY:XU	BBG005QKW3W8
4568JPY:XV	BBG005QKW3Y6
4568JPY:EU	BBG005QKW4W6
4568:JW	BBG00875HD42
D4S:QT	BBG00D0NBX05
4568EUR:EO	BBG00D0NQWZ3
4568EUR:XH	BBG00D0NQX54
4568EUR:XF	BBG00D0NQX90
4568EUR:XE	BBG00D0NQXD5
4568EUR:XJ	BBG00D0NQXF3
4568EUR:XL	BBG00D0NQXG2
4568EUR:XG	BBG00D0NQXH1
4568EUR:XO	BBG00D0NQXJ9
4568EUR:XS	BBG00D0NQXN4
4568EUR:XA	BBG00D0NQXP2
4568EUR:E1	BBG00D0NQXQ1
4568EUR:XT	BBG00D0NQXR0
4568EUR:XW	BBG00D0NQXS9
4568EUR:XU	BBG00D0NQXT8
4568EUR:XV	BBG00D0NQXV5
4568EUR:EU	BBG00D0NQXX3
D4S:GZ	BBG00FGWY4Q4
4568JPY:XX	BBG00JN850Y2
4568EUR:XX	BBG00JN8HR89
4568USD:X2	BBG00K62KFT7
4568USD:XB	BBG00K62KFV4
4568USD:XH	BBG00K62KFX2
4568USD:XF	BBG00K62KFZ0
4568USD:XE	BBG00K62KG15
4568USD:XJ	BBG00K62KG24
4568USD:XL	BBG00K62KG33
4568USD:XG	BBG00K62KG42
4568USD:XO	BBG00K62KG51
4568USD:XS	BBG00K62KG97
4568USD:XA	BBG00K62KGB4
4568USD:E1	BBG00K62KGC3
4568USD:XT	BBG00K62KGD2
4568USD:XW	BBG00K62KGF0
4568USD:XU	BBG00K62KGG9
4568USD:XV	BBG00K62KGH8
4568USD:XM	BBG00K62KGJ6
4568USD:XQ	BBG00K62KGL3
4568USD:XX	BBG00K62KGM2
4568USD:XZ	BBG00K62KGN1
4568USD:EU	BBG00K62KGQ8
D4S:TH	BBG00PYS9PX4
4568JPY:X2	BBG00Q6RTVL3
4568JPY:EP	BBG00QNTRT19
4568JPY:EZ	BBG00QNTRT37
D4S:LA	BBG018H8BJ65
D4S:LU	BBG018J1ZLS3
4568:JV	BBG0193R9M53
D4S:BU	BBG01BPDCRM1
4568N:MM	BBG01C70D358
4568N:MF	BBG01C70D367
4568N:MU	BBG01C70D376

All fundamentals about Daiichi Sankyo Co

Our stock analysis for Daiichi Sankyo Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Daiichi Sankyo Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

The Modern Financial Terminal

Trusted by leading companies and financial institutions

Daiichi Sankyo Co Stock 4568.T

Price

Price

Ticker4568.T

ISINJP3475350009

Daiichi Sankyo Co stock price

Price

Overview

Intraday Feature

Total Return and Relative Price Change

Interpretation and Investment

Daiichi Sankyo Co Revenue, EBIT, Net Income

Daiichi Sankyo Co Income Statement, Balance Sheet, Cash Flow Statement

Keystats

Revenue and Growth

Gross Margin

EBIT and EBIT Margin

Income and Growth

Shares Outstanding

Interpreting Year to Year Comparison

Expectations and Predictions

Balance Sheet

Understanding the Balance Sheet

Assets

Liabilities

Equity

Year-to-Year Analysis

Interpreting the Data

Daiichi Sankyo Co stock margins

Daiichi Sankyo Co Stock Sales Revenue, EBIT, Earnings per Share

Daiichi Sankyo Co business model

Daiichi Sankyo Co SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

The World’s Best Investors Are On Eulerpool

Daiichi Sankyo Co Eulerpool Fair Value

Fair Value

Understanding Fair Value

Income-Based Fair Value

Revenue-Based Fair Value

Dividend-Based Fair Value

Expectations and Forecasts

Comparative Analysis

Daiichi Sankyo Co historical P/E ratio, EBIT multiple, and P/S ratio

The World’s Best Investors Are On Eulerpool

Daiichi Sankyo Co shares outstanding

Daiichi Sankyo Co stock splits

Daiichi Sankyo Co dividend history and estimates

Daiichi Sankyo Co dividend payout ratio

The World’s Best Investors Are On Eulerpool

Daiichi Sankyo Co Earnings Calls

Daiichi Sankyo Co Earnings Estimates

Eulerpool ESG Scorecard© for the Daiichi Sankyo Co stock

Eulerpool World ESG Rating (EESG©)

92/ 100

🌱 Environment

👫 Social

🏛️ Governance

Environment

Social

Governance (Corporate Governance)

Daiichi Sankyo Co shareholders

Daiichi Sankyo Co Executives and Management Board

Mr. Sunao Manabe

Mr. Hiroyuki Okuzawa

Mr. Shoji Hirashima

Mr. Takashi Fukuoka

Mr. Takashi Matsumoto

Most common questions regarding Daiichi Sankyo Co

What is the business model of Daiichi Sankyo Co?

In which industries is Daiichi Sankyo Co primarily active?

Who are the main competitors of Daiichi Sankyo Co in the market?

What is the history and background of the company Daiichi Sankyo Co?

What significant milestones has the company Daiichi Sankyo Co achieved?

In which countries and regions is Daiichi Sankyo Co primarily present?

What values and corporate philosophy does Daiichi Sankyo Co represent?

Ticker
4568.T

ISIN
JP3475350009